Literature DB >> 29989483

Involvement of prelimbic 5-HT7 receptors in the regulation of anxiety-like behaviors in hemiparkinsonian rats.

Cheng Xue Du1, Yuan Guo1, Qiao Jun Zhang2, Jin Zhang1, Shu Xuan Lv1, Jian Liu1,3.   

Abstract

OBJECTIVE: At present, little is known about the role of serotonin7 (5-HT7) receptor in anxiety, particularly in Parkinson's disease-related anxiety. Here, we tested whether 5-HT7 receptors in the prelimbic (PrL) cortex are involved in the regulation of anxiety-like behaviors in sham-operated rats and rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle (MFB).
METHODS: The open field and elevated plus maze (EPM) tests were performed to study the influence of MFB lesion and intra-PrL injection of 5-HT7 agonist AS19 (0.5, 1 or 2 μg/rat) and antagonist SB269970 (1.5, 3 or 6 μg/rat) on anxiety-like behaviors. Additionally, changes in monoamine levels in limbic and limbic-related brain regions were observed after intra-PrL injection of AS19 (2 μg/rat) and SB269970 (6 μg/rat).
RESULTS: The MFB lesion induced anxiety-like behaviors compared to sham-operated rats. Intra-PrL injection of AS19 showed anxiolytic effects by the open field and EPM tests in two groups of rats, and administration of SB269970 showed anxiogenic responses. However, the doses producing these effects in the lesioned rats were higher than those in sham-operated rats. Neurochemical results showed that intra-PrL injection of AS19 increased dopamine, 5-HT and noradrenaline (NA) levels in the medial prefrontal cortex, ventral hippocampus and amygdala in two groups of rats, whereas SB269970 decreased 5-HT and NA levels in these brain regions. DISCUSSION: 5-HT7 receptors in the PrL are involved in the regulation of anxiety-like behaviors, which is attributable to changes in dopamine, 5-HT and NA levels in the limbic and limbic-related brain regions after activation and blockade of 5-HT7 receptors. ABBREVIATIONS: 6-OHDA: 6-hydroxydopamine; DMSO: dimethyl sulfoxide; DA: dopamine; EPM: elevated plus maze; MFB: medial forebrain bundlem; PFC: medial prefrontal cortex; NA: noradrenaline; PD: Pakinson's disease; PrL: prelimbic; 5-HT: serotonin; vHip: ventral hippocampus.

Entities:  

Keywords:  5-HT7 receptors; Parkinson’s disease; Prelimbic cortex; anxiety; monoamines

Mesh:

Substances:

Year:  2018        PMID: 29989483     DOI: 10.1080/01616412.2018.1493962

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  4 in total

Review 1.  Medial prefrontal cortex in neurological diseases.

Authors:  Pan Xu; Ai Chen; Yipeng Li; Xuezhi Xing; Hui Lu
Journal:  Physiol Genomics       Date:  2019-08-02       Impact factor: 3.107

2.  Anxiety in Parkinson's Disease: Correlation with Depression and Quality of Life.

Authors:  Ankush Upneja; Birinder S Paul; Dinesh Jain; Rupesh Choudhary; Gunchan Paul
Journal:  J Neurosci Rural Pract       Date:  2021-03-24

Review 3.  Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

Authors:  Gregory M Pontone; Nadeeka Dissanayka; Liana Apostolova; Richard G Brown; Roseanne Dobkin; Kathy Dujardin; Joseph H Friedman; Albert F G Leentjens; Eric J Lenze; Laura Marsh; Lynda Mari; Oury Monchi; Irene H Richard; Anette Schrag; Antonio P Strafella; Beth Vernaleo; Daniel Weintraub; Zoltan Mari
Journal:  NPJ Parkinsons Dis       Date:  2019-12-11

Review 4.  Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

Authors:  Kathy Dujardin; Véronique Sgambato
Journal:  Front Neurosci       Date:  2020-01-29       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.